ArticleAmerican journal of nuclear medicine and molecular imaging2021
Preclinical development and characterisation of
Article in American journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04992715 (A Single-arm, Phase II Study to Evaluate PD-L1 Expression in Non-Small Cell Lung Cancer Using the 99mTc Labelled Anti-PD-L1 Single Domain Antibody), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-arm, Phase II Study to Evaluate PD-L1 Expression in Non-Small Cell Lung Cancer Using the 99mTc Labelled Anti-PD-L1 Single Domain Antibody (NM-01)
Who cites it
16 citing papers in PubMed.
- PD-L1 imaging with [British journal of cancer · 2025Trial
- Advances in PD-L1 Targeted Molecular Imaging Radiotracers Research: From Preclinical Exploration to Clinical Application.Molecular imaging and biology · 2026Review
- Nuclear medicine in predicting hepatocellular carcinoma response.Nuclear medicine communications · 2026Review
- Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.MedComm · 2026Review
- The role of the tumor microenvironment in mediating radiopharmaceutical therapy: bridging nuclear medicine and cancer immunotherapy.Military Medical Research · 2026Review
- The promising potential of camelid nanobodies for nuclear medicine.European journal of nuclear medicine and molecular imaging · 2025Article
- Myomedin variants developed for in vitro PD-L1 diagnostics in tissue samples of non-small cell lung carcinoma patients.Journal of translational medicine · 2025Article
- Preclinical evaluation and preliminary clinical study ofCancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Article
- The Role of Nuclear Medicine in Predicting Treatment Response to Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma: A Narrative Review.Journal of hepatocellular carcinoma · 2025Review
- Review
- Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.Frontiers in medicine · 2024Review
- Inter-rater and intra-rater agreement of [EJNMMI research · 2023Article
- [EJNMMI research · 2023Article
- Radioimmunotherapy study ofEJNMMI research · 2022Article
- High-performance renal imaging with a radiolabeled, non-excretable chimeric fusion protein.Theranostics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The level of expression of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) is a predictive biomarker for cancer immunotherapy, however, its detection remains challenging due to tumour heterogeneity and the influence from the binding of therapeutic agents. We recently developed [
Indexed as
Identifiers
34234994PMC8255215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.